Paladin introduces grass pollen allergy medication in Canada

Specialty pharmaceutical company Paladin Labs has introduced first allergen immunotherapy tablet, Oralair, against grass pollen allergies in Canada.

The sublingual once daily medication should be administered from four months prior to the onset of season and continued all through the seasonal period.

Paladin Labs interim president and chief executive officer Mark Beaudet said, “With Oralair, Canadian patients now have a safe, effective and convenient way to relieve their seasonal grass allergy symptoms.”

Oralair demonstrated significant efficacy and safety profile in five placebo controlled trials in which subjects from Europe and North America were involved.

Immunotherapy medication constitutes five grass pollen extracts rye grass (Lolium perenne), meadow grass (Poa pratensis), timothy grass (Phleum pratense), cocksfoot (Dactylis glomerata) and sweet vernal grass (Anthoxanthum odoratum).